• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Augmedix Inc.

    10/2/24 9:14:24 AM ET
    $AUGX
    Business Services
    Consumer Discretionary
    Get the next $AUGX alert in real time by email
    POS AM 1 d848728dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on October 2, 2024

    Registration No. 333-264337

    Registration No. 333-251310

    Registration No. 333-272081

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-264337

    Post-Effective Amendment No. 2 to Form S-1 on Form S-3 Registration Statement No. 333-251310

    Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-272081

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Augmedix, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   83-3299164

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    111 Sutter Street, Suite 1300

    San Francisco, California 94104

    (888) 669-4885

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Daniel Brian

    Augmedix, Inc.

    Chief Financial Officer, Treasurer and Secretary

    111 Sutter Street, Suite 1300

    San Francisco, California 94104

    (888) 669-4885

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Marshall Shaffer

    Kirkland & Ellis LLP

    601 Lexington Avenue

    New York, NY 10022

    (212) 446 4800

     

     

    Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statements.

    (Approximate date of commencement of proposed sale to the public)

     

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    These post-effective amendments (these “Post-Effective Amendments”) related to the following Registration Statements on Form S-3 (collectively, the “Registration Statements”) previously filed by Augmedix, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “SEC”) are being filed to withdraw and remove from registration any and all of the securities of the Registrant registered but unsold or otherwise unissued under each such Registration Statements as of the date hereof:

     

      •  

    Registration Statement on Form S-3 (File No. 333-264337), which was filed with the SEC on April 15, 2022, registering up to $125,000,000 of shares of common stock, par value $0.0001 per share (“Common Stock”), preferred stock, par value $0.0001 per share, debt securities and warrants;

     

      •  

    Registration Statement on Form S-1 on Form S-3 (File No. 333-251310), which was filed with the SEC on July 22, 2022 and amended by Post-Effective Amendment No. 1, filed with the SEC on July 27, 2022, registering 29,145,527 shares of Common Stock; and

     

      •  

    Registration Statement on Form S-3 (File No. 333-272081), which was filed with the SEC on May 19, 2023, registering 9,375,342 shares of Common Stock.

    On October 2, 2024, pursuant to an Agreement and Plan of Merger, dated as of July 19, 2024, by and among the Company, Commure, Inc., a Delaware corporation (“Parent”), and Anderson Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Company (the “Merger”), with the Company surviving the Merger as a direct wholly owned subsidiary of Parent.

    As a result of the Merger, the Company has terminated any and all offerings of its securities pursuant to the Registration Statements. In accordance with the undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unissued at the termination of the offerings, by filing these Post-Effective Amendments, the Company hereby removes from registration all securities registered but unsold or otherwise unissued under the Registration Statements, if any, as of the date hereof, and the Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by the Company pursuant to the Registration Statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on the 2nd day of October, 2024.

     

    AUGMEDIX, INC.
    By:  

    /s/ Daniel Brian

      Daniel Brian
      Chief Financial Officer, Treasurer and Secretary

     

    *

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment.

    Get the next $AUGX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AUGX

    DatePrice TargetRatingAnalyst
    7/22/2024Buy → Hold
    Lake Street
    7/22/2024$3.00 → $2.35Buy → Neutral
    B. Riley Securities
    5/14/2024$5.00Buy → Hold
    Maxim Group
    5/14/2024$5.00 → $1.50Outperform → In-line
    Evercore ISI
    4/3/2024$5.50Buy
    B. Riley Securities
    12/15/2023$6.00In-line
    Evercore ISI
    3/7/2022$6.00Buy
    Lake Street
    1/21/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $AUGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Commure Completes Merger with Augmedix

      SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

      10/2/24 8:23:42 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

      SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. "We believe we are approaching the proposed combination with Commure, Inc. from a position of strength, with consistent double-digit revenue growth and improving gross margins," commented Manny Krakaris, Augmedix CEO. "Together, we believe we will be well-positioned to continue to streamline the medical documentation ecosystem with a growing base of health system customers, solid partners, and proven solutions. As part of Commure, we expect to scale our ambient documentation solu

      8/12/24 4:01:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

      8/6/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Augmedix Inc.

      15-12G - Augmedix, Inc. (0001769804) (Filer)

      10/15/24 9:32:28 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Augmedix Inc.

      EFFECT - Augmedix, Inc. (0001769804) (Filer)

      10/4/24 12:15:04 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Augmedix Inc.

      EFFECT - Augmedix, Inc. (0001769804) (Filer)

      10/4/24 12:15:02 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ginocchio Paul bought $48,500 worth of shares (10,000 units at $4.85), increasing direct ownership by 8% to 128,000 units (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      11/27/23 7:00:06 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Redmile Group, Llc bought $6,000,000 worth of shares (1,500,000 units at $4.00) (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      11/22/23 4:15:24 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Augmedix downgraded by Lake Street

      Lake Street downgraded Augmedix from Buy to Hold

      7/22/24 8:25:03 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Augmedix from Buy to Neutral and set a new price target of $2.35 from $3.00 previously

      7/22/24 8:02:58 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix downgraded by Maxim Group with a new price target

      Maxim Group downgraded Augmedix from Buy to Hold and set a new price target of $5.00

      5/14/24 8:17:17 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc returned $75,402,504 worth of shares to the company (32,086,172 units at $2.35) (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 5:01:03 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form 4 filed by Director Faulkner Robert C.

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 5:00:14 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Director Febbo William J returned $382,070 worth of shares to the company (162,583 units at $2.35), closing all direct ownership in the company (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 1:17:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Augmedix to Join Forces with Commure

      SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction, and Augmedix will become a wholly-owned subsidiary of Commure. The purchase price represents a premium of approximately 169% over the volume weighted average price

      7/19/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer

      SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient artificial intelligence (AI) medical documentation and data solutions, today announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. "Welcoming Dr. Stinard to join Augmedix in this new role is an exciting step forward in implementing advanced AI technolog

      5/29/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

      SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies' combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products. "We are thrilled to join forces with SADA, to partner with an organization that has a nationwide reach to health systems, and also to leverage their prowess in frontier cloud infr

      4/4/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Financials

    Live finance-specific insights

    See more
    • Commure Completes Merger with Augmedix

      SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

      10/2/24 8:23:42 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

      8/6/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

      SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. "Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins," commented Manny Krakaris, Augmedix CEO. "We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products." "We a

      5/13/24 4:03:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

      SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

      10/4/24 5:00:14 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by Augmedix Inc.

      SC 13G - Augmedix, Inc. (0001769804) (Subject)

      7/29/24 5:23:20 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

      SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

      7/19/24 7:45:47 PM ET
      $AUGX
      Business Services
      Consumer Discretionary